Acutaas Chemical
Acutaas Chemical Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The company has consistently guided a 25% CAGR revenue growth and is open to revising upward if business potential exceeds this (Page 17). Revenue growth guidance for FY '27 is 25% CAGR, in line with the company’s history of over a decade.
From Acutaas Chemical's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company has consistently guided a 25% CAGR revenue growth and is open to revising upward if business potential exceeds this (Page 17).
- Growth drivers for FY '27 and beyond include:
- - Electrolyte additive division (battery chemicals).
- - Pharma intermediate business, which is the biggest growth engine.
- - Semiconductor chemical business, starting with BFC and Indichem JV in 2-3 years (Page 15).
- CDMO business has a long-term 10-year contract ensuring visibility and revenue stability; with multiple new products in validation/commercial phases (Page 14-15).
- Electrolyte additive capacity expansion underway; capacity of 2,000 MT indicates significant revenue potential (Page 14).
- Seasonality effect expected but new contracts like Fermion ramp-up may reduce Q1 dips (Page 17).
- New versatile R&D centre and infrastructure expansions underway to support growth over next 5-10 years (Page 6).
- Overall, 25% revenue growth is expected until at least FY '28, supported by multiple growth engines and product portfolio upgrades.
Profitability & Margins
See what Acutaas Chemical said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY '26 capex was INR195 crores focused on Jhagadia site for battery chemical project and pilot plant at Sachin site, plus maintenance.
- Spillover capex of around INR50 crores related to electrolyte additive and pilot plant expected in FY '27.
- FY '27 planned capex around INR90 crores (INR50 crores spillover + INR40 crores maintenance), excluding new R&D center costs.
- New versatile R&D center planned with ~10x capacity expansion, covering pharmaceuticals, battery chemicals, semiconductors, electronics, cosmetics, and more.
- Continued investment in the South Korea joint venture Indichem with INR190 crores invested in FY '26; plant commissioning expected in second half of calendar 2026.
- Evaluating land acquisition for further infrastructure development to support long-term growth.
- Strategic migration from commodity chemical products to higher-value differentiated products ongoing.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Acutaas Chemical said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- For the CDMO business, Acutaas Chemicals has a confirmed long-term supply contract in place for 10 years with their first customer, providing good visibility and backlog.
- The electrolyte additive segment has customer contracts already signed, covering the full 2,000 metric ton capacity for at least the next 3 years.
- There are four additional CDMO products beyond the Fermion contract, validated and awaiting regulatory approval, with each expected to have a revenue potential of INR 50-100 crores at peak levels.
- The production for these CDMO products has started, and commercial revenues are expected to ramp up in FY'27 with meaningful contributions from both CDMO and electrolyte additive businesses.
- The company maintains a healthy and secured order book backed by contracts for multiple years across their CDMO and specialty chemical verticals.
Acutaas Chemical — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹433 Cr, net profit ₹134 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Acutaas Chemicals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
- Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
- RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
- Sai Parenterals Ltd (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…
Frequently Asked Questions
What were Acutaas Chemical Q4 FY26 results?
The company has consistently guided a 25% CAGR revenue growth and is open to revising upward if business potential exceeds this (Page 17). Revenue growth guidance for FY '27 is 25% CAGR, in line with the company’s history of over a decade.
What is Acutaas Chemical share price analysis?
Acutaas Chemical currently shows a neutral. The stock trades at a P/E of 67.2 with a market cap of ₹25,945 Cr. Investors should review the full earnings analysis for detailed insights.
Is Acutaas Chemical planning capital expenditure?
FY '26 capex was INR195 crores focused on Jhagadia site for battery chemical project and pilot plant at Sachin site, plus maintenance.
Keep Acutaas Chemical on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.